

Serial No.: 09/318,870

Page 2

The following Listing of the Claims will replace all prior versions and all prior listings of the claims in the present application:

Listing of The Claims:

1. (Currently Amended) A method of stimulating an immune response ~~in a mammal~~ to an antigen, the method comprising

administering to a mammal a composition comprising a cell comprising said antigen  
admixed with

an engineered cytokine,

~~coated cell comprising said antigen, wherein said cytokine of said cytokine-coated cell is~~  
~~exogenous to and wherein said engineered cytokine is bound to said cell, and wherein said~~  
~~engineered cytokine comprises (1) a cytokine, and (2) a moiety heterologous to said cytokine~~  
~~wherein said moiety binds to said cell when said engineered cytokine is mixed with said cell~~  
~~exogenously, and wherein an immune response is stimulated in said mammal to said antigen.~~

2. (Currently Amended) A method of stimulating an immune response ~~in a mammal~~ to an antigen, the method comprising

admixing a cell comprising said antigen with a cytokine which is exogenous to said cell  
and which binds to said cell producing a cytokine-coated cell; and

administering to a mammal ~~a composition comprising said cytokine-coated cell, wherein~~  
~~said cytokine of said cytokine-coated cell is exogenous to and bound to said cell, wherein said~~  
~~cytokine-coated cell comprises said antigen and is admixed with an engineered cytokine, and~~  
wherein an immune response is stimulated in said mammal to said antigen.

3. (Previously presented) The method of claim 1 or claim 2 wherein said composition further comprises an opsonin-enhanced cell.

BEST AVAILABLE COPY

Serial No.: 09/318,870

Page 3

4. (Previously presented) The method of claim 3 wherein said opsonin of said opsonin-enhanced cell is selected from the group consisting of mannose binding protein or the alpha' chain of C3b.
5. (Previously presented) The method of any one of claims 1 or 2 wherein said cytokine of said cytokine-coated cell comprises a lipid.
6. (Previously presented) The method of claim 5 wherein said cytokine comprises a GPI moiety.
7. (Previously presented) The method of claim 5 wherein said cytokine comprises a fatty acid.
8. (Previously presented) The method of claim 7 wherein said fatty acid is palmitate.
- 9-12. (Cancelled)
13. (Currently Amended) A method of stimulating an immune response in a mammal to an antigen, the method comprising  
  
administering to the a mammal a composition comprising a cytokine-coated cell comprising said antigen admixed with  
  
an engineered cytokine, wherein said cytokine of said cytokine-coated cell is exogenous to and  
  
wherein said engineered cytokine is bound to said cell, and wherein said engineered cytokine comprises (1) a cytokine which is a ligand for the GM-CSF receptor, and (2) a moiety heterologous to said cytokine wherein said moiety binds to said cell when said engineered cytokine is mixed with said cell exogenously, and wherein said cytokine is a ligand for the GM-CSF receptor, and wherein an immune response is stimulated in said mammal to said antigen.
14. (Original) The method of claim 13, wherein said ligand for the GM-CSF receptor is GM-CSF.

Serial No.: 09/318,870

Page 4

15. (Currently amended) A method of stimulating an immune response ~~in a mammal~~ to an antigen, the method comprising:

administering to a mammal a composition comprising a ~~cytokine-coated cell~~ comprising said antigen admixed with

an engineered cytokine, ~~wherein said cytokine of said cytokine-coated cell is exogenous to and~~

wherein said engineered cytokine is bound to said cell, wherein said engineered cytokine comprises (1) a cytokine which is a ligand for one of the following receptors: the IL-2 receptor, the IL-4 receptor, the IL-6 receptor, the IL-10 receptor, the IL-12 receptor, the TNF- $\alpha$  receptor, the IFN- $\gamma$  receptor, a chemokine receptor and (2) a moiety heterologous to said cytokine wherein said moiety binds to said cell when said engineered cytokine is mixed with said cell exogenously, and wherein said cytokine is a ligand for one of the following receptors: the IL-2 receptor, the IL-4 receptor, the IL-6 receptor, the IL-10 receptor, the IL-12 receptor, the TNF- $\alpha$  receptor, the IFN- $\gamma$  receptor, a chemokine receptor an immune response is stimulated in said mammal to said antigen.

16. (Previously presented) The method of claim 15, wherein said ligand is selected from the group consisting of: IL-2, IL-4, IL-6, IL-10, IL-12, TNF- $\alpha$ , IFN- $\gamma$ , or a chemokine.

17. (Previously presented) The method of any one of claims 1 or 13, wherein said cell of said cytokine-coated cell is a pathogenic cell.

18. (Original) The method of claim 17 wherein said pathogenic cell is a malignant tumor cell.

19. (Previously presented) The method of claim 17 wherein said cell of said pathogenic cell is selected from the group consisting of: a bacterium, a virus, a fungus, and a cell of a parasite.

20. (Previously presented) The method of claim 17, wherein said composition further comprises an opsonin-enhanced pathogenic cell.

Serial No.: 09/318,870

Page 5

21. (Currently amended) A method of stimulating an immune response ~~in a mammal~~ to an antigen, the method comprising administering to a mammal a vaccine composition comprising an opsonin-enhanced pathogenic cell and a cytokine-coated pathogenic cell, wherein said cytokine of said cytokine-coated cell is exogenous to and bound to said cell, wherein said opsonin is selected from the group consisting of mannose binding protein or the alpha' chain of C3b.
22. (Previously presented) The method of any one of claims 1 or 13 wherein said cytokine-coated cell is substantially unable to divide in vitro.
23. (Previously presented) The method of any one of claims 1 or 13, wherein said cytokine-coated cell is attenuated.
24. (Previously presented) The method of any one of claims 1 or 13, wherein said cytokine is an antitumor cytokine.
25. (Previously presented) The method of any one of claims 1 or 13, wherein said cytokine is extremely bioactive, natively bioactive, or suprabioactive.

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**